Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients

Dec 2, 2021Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association

Beinaglutide Compared to Metformin for Weight Loss in Overweight and Obese People Without Diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Patients treated with beinaglutide lost an average of 9.5% of their body weight compared to 5.1% with metformin.

Beinaglutide resulted in a weight loss difference of approximately 4.5 kg compared to metformin.
In the beinaglutide group, 90.6% of patients lost at least 5% of their body weight, compared to 46.9% in the metformin group.
The treatment with beinaglutide led to a significant reduction in body mass index, waist circumference, and body fat percentage.
Beinaglutide treatment was associated with decreased serum insulin levels and improved insulin resistance.
Weight loss with beinaglutide primarily came from the reduction of fat mass.

AI simplified

PURPOSE: We compared the efficacy and safety of beinaglutide, a glucagon-like peptide-1 (GLP-1) analogue with metformin in lowering the bodyweight of patients who were overweight/obese and non-diabetic.

PATIENTS AND METHODS: Seventy-eight non-diabetic patients were randomly selected and beinaglutide or metformin was administered for 12 weeks. The primary endpoints were changes in body weight and the proportions of patients who lost≥5 and≥10% of their baseline body weights.

RESULTS: A total of 64 patients completed the study; patients in the beinaglutide group exhibited more bodyweight loss than those in the metformin group [(9.5±0.8%; 9.1±0.9 kg) and (5.1±0.9%; 4.5±0.8 kg), respectively, corresponding to a difference of approximately 4.5 kg (95% confidence interval, 2.2-6.9 kg;<0.01)]. In the beinaglutide group, 90.6 and 40.6% of the patients lost≥5 and≥10% of their body weight, respectively, whereas, in the metformin group, these rates were 46.9 and 12.5%, respectively (<0.01 and0.05). Weight loss following beinaglutide treatment mainly resulted from the loss of fat mass. Compared to metformin, beinaglutide induced a greater decrease in the body mass index, weight circumference, percent body fat, and body fat mass (total, trunk, limb, android, and gynoid). Additionally, beinaglutide decreased serum insulin levels and ameliorated insulin resistance. P P P<

CONCLUSIONS: Beinaglutide is more efficient than metformin at reducing weight and fat mass in patients who are overweight/obese and non-diabetic. Beinaglutide may be a useful therapeutic option for overweight/obesity control in the Chinese population.

Key numbers

4.5 kg

Weight Loss Increase

Mean weight loss difference between beinaglutide and metformin groups.

90.6%

Weight Loss ≥5%

Proportion of patients losing ≥5% body weight in beinaglutide group vs. metformin group.

40.6%

Weight Loss ≥10%

Proportion of patients losing ≥10% body weight in beinaglutide group vs. metformin group.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text ↗

Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Key numbers

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief